Fatal Interruption of a 3TC-containing Regimen in a HIV-infected Patient Due to Re-activation of Chronic Hepatitis B Virus Infection

References

• Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188: 571–7.
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996; 125: 705–12.
   PubMed Web of Science ®Google Scholar
• Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clinical Infectious Diseases 1999; 28: 1032–5.
   Google Scholar
• Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002; 51: 597–9.
   Google Scholar
• Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999; 180: 607–13.
   Google Scholar
• Liu X, Schinazi RF. Hepatitis B virus resistance to lamivudine and its clinical implications. Antivir Chem Chemother 2002; 13: 143–55.
   PubMedGoogle Scholar
• Yuen MF, Kato T, Mizokami M, Chan AO, Yuen JC, Yuan HJ, et al. Clinical outcome and virological profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003; 39: 850–5.
   PubMedGoogle Scholar
• Michalak TI. Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. Immunol Rev 2000; 174: 98–111.
   PubMedGoogle Scholar
• Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci USA 1999; 96: 10958–61.
   PubMed Web of Science ®Google Scholar
• Chulanov VP, Shipulin GA, Schaefer S, Gerlich WH. Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without co-infection by other hepatitis viruses. J Med Virol 2003; 69: 313–23.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson AS, Ho DD. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 2003; 77: 5037–8.
   Google Scholar
• Rockstroh JK. Management of hepatitis B and C in HIV co-infected patients. J Acquir Immune Defic Syndr 2003; (34 Suppl 1): S59–65.
   Google Scholar
• Wolters LM, Niesters HG, de Man RA, Schalm SW. Antiviral treatment for human immunodeficiency virus patients coinfected with hepatitis B virus: combined effect for both infections, an obtainable goal? Antiviral Res 1999; 42: 71–6.
   PubMedGoogle Scholar
• Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus- infected patients. Hepatology 1999; 30: 1302–6.
   Google Scholar
• Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105–17.
   PubMed Web of Science ®Google Scholar
• Altfeld M, Rockstroh JK, Addo M, Kupfer B, Pult I, Will H, Spengler U. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol 1998; 2: 306–9.
   Google Scholar
• Wong VW, Chan HL, Wong ML, Tam JS, Leung NW Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther 2004; 19: 323–9.
   PubMedGoogle Scholar
• Wiegand J, Tischendorf JJ, Nashan B, Klempnauer J, Flemming P, Niemann P, et al. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. J Gastroenterol 2004; 42: 15–8.
   Google Scholar
• Someya T, Suzuki Y, Arase Y, Kobayashi M, Suzuki F, Tsubota A, et al. Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant. J Gastroenterol 2001; 36: 133–6.
   PubMedGoogle Scholar
• Lee WC, Wu MJ, Cheng CH, Chen CH, Shu KH, Lian JD. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001; 38: 1074–81.
   PubMedGoogle Scholar
• Tsang SW, Chan HL, Leung NW, Chau TN, Lai ST, Chan FK, Sung JJ. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Aliment Pharmacol Ther 2001; 15: 1737–44.
   Google Scholar
• Torii N, Hasegawa K, Ogawa M, Hashimo E, Hayashi N. Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B. Hepatol Res 2002; 24: 34.
   Google Scholar
• Chan HL, Tsang SW, Hui Y, Leung NW, Chan FK, Sung JJ. The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J Viral Hepat 2002; 9: 424–8.
   PubMedGoogle Scholar
• Petrelli E, Balducci M, Pieretti C, Rocchi MB, Clementi M, Manzin A. Lamivudine treatment failure in preventing fatal outcome of de novo severe acute hepatitis B in patients with haematological diseases. J Hepatol 2001; 35: 823–6.
   PubMed Web of Science ®Google Scholar
• Acute Hepatic Failure Study Group. Failure of specific immunotherapy in fulminant type B hepatitis. Ann Intern Med 1977; 86: 272–7.
   PubMedGoogle Scholar
• Ristig M, Drechsler H, Crippin J, Lisker-Melman M, Tebas P. Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus. AIDS Patient Care STDS 2003; 17: 439–42.
   Google Scholar